Changes in Life Quality of Chronic Kidney Disease Patients with Hemodialysis Who Are Given Vitamin B1, B6, and B12 Parenterally by Angela, Tjung & Pinzon, Rizaldy Taslim
Pinzon et al                                               Journal of Drug Delivery & Therapeutics. 2020; 10(2):153-157 
ISSN: 2250-1177                                      [153]                                    CODEN (USA): JDDTAO 
Available online on 15.03.2020 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                     Research Article  
Changes in Life Quality of Chronic Kidney Disease Patients with 
Hemodialysis Who Are Given Vitamin B1, B6, and B12 Parenterally  
Rizaldy Taslim Pinzon, Angela  
Duta Wacana Christian University School of Medicine Yogyakarta Indonesia 
 
ABSTRACT  
Background: Chronic kidney disease (CKD) is a disease that causes a progressive decrease in kidney function, which can end in kidney failure  
disease and will have an impact on decreasing quality of life. Previous research has shown that by giving vitamins B1, B6, and B12 can improve 
quality of life. 
Aim: To measure changes in quality of life in patients with chronic kidney disease who were given vitamins B1, B6, and B12 parenterally. 
Material and Methods: This study used quasi experimental (one group pre and post test) in 117 patients who were selected in Bethesda 
Hospital and Panti Rapih Hospital Yogyakarta hemodialysis unit. Patients were given vitamins B Combination injections twice a week in each 
hemodialysis for 4 weeks. Quality of life was measured by SF-8 questionnaire on the first day of hemodialysis before given vitamins (pre-test) 
and on the 30th day, after eight injection of vitamins B1, B6, and B12 (post test). 
Results: The mean age of observed patients were 51.58 ± 12.51 years. From 117 patients, 73 patients (62,4%) were male and 44 patients 
(37.6%) were female. The improvement in overall quality of life in patients was not significant (p= 0.055). Quality of life improvement was only 
significant in the male group (p = 0.016). 
Conclusion: There was no significant difference after 4-weeks-injections of vitamins B Combination to the overall quality of life in chronic 
kidney disease patients undergoing hemodialysis. But there was found a significant improvement in quality of life in the male patients with 
chronic kidney disease who had hemodialysis. 
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INTRODUCTION 
Chronic kidney disease (CKD) is a disease that causes a 
progressive decrease in kidney function with diverse 
etiologies, which can end in kidney failure.[1] To determine 
changes in quality of life in CKD patients, can be measured 
using an SF-8 questionnaire developed to replicate SF- 36. In 
this questionnaire there are several domains that contain 
perceptions of general health, physical function, limited role 
due to physical health, pain, vitality, social role functions, 
mental health and role limitations due to emotional 
problems. The SF-8 questionnaire has been proven valid in 
assessing general physical health and mental health in the 
population.[2]  
Assessing the mortality rate in chronic kidney disease 
patients each year and considering the importance of life 
quality assessments for evaluating therapy in patients with 
chronic kidney disease and also to determine the 
effectiveness of giving a combination of vitamin B (B1, B6, 
and B12) to the quality of life of CKD patients. 
 
MATERIALS AND METHODS 
The research design used was analytic with quasi 
experimental methods with one group pre and post test 
design. Retrieval of data in this study is in the form of SF-8 
(Short-Form 8) quality of life questionnaire containing 8 
questions whose data was collected at the Hemodialysis unit 
of Bethesda Hospital and Yogyakarta Panti Rapih Hospital. 
Vitamin administration is carried out for 1 month as many as 
eight times parenteral injection, every time the respondent 
performs hemodialysis (twice a week). Filling out the 
questionnaire was done twice, namely before being given the 
first injection of vitamins and after administration of 
vitamins B1, B6, and B12 (Neurobion Forte 5000mg 
injection) last time in the fourth week. Furthermore, an 
analysis of quality of life will be carried out before and after 
parenteral administration of vitamins B1, B6, and B12. 
Ethical approval: Ethical clearance was obtained from 
Faculty of Medicine Duta Wacana Christian University, 
Yogyakarta, Indonesia as the institutional ethics clearance 
comittee (Ethical Clearance 793/C.16/FK/2018). 
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RESULTS
Table 1. Basic characteristics of respondents 
Characteristics of Respondents  n=117 % 
Sex 
 
Male 
Female 
73 62,4% 
44 37,6% 
 
Age, Mean±SD 
 
51,58±12,51 years 
Minimum : 19 years 
Maximum: 82 years 
 
 
Hemoglobin, Mean±SD 
9,22±1,48 
Minimum : 5,5 
Maximum: 13,20 
 
 
 
Comorbidities 
Hypertensive 
- Yes 
- No 
 
101 
16 
 
86,3% 
13,7% 
 
Diabetes Mellitus 
- Yes 
- No 
 
40 
77 
 
34,2% 
65,8% 
 
Cardiovascular 
- Yes 
- No 
 
31 
86 
 
26,5% 
73,5% 
 
 
Stroke 
- Yes 
- No 
8 
109 
6,8% 
93,2% 
 
Congenital Kidney 
Disease 
- Yes 
- No 
 
2 
115 
 
1,7% 
98,3% 
 
Recurent Kidney Stone 
- Yes 
- No 
 
9 
108 
 
7,38% 
92,3% 
 
Anemia 
- Yes 
- No 
 
111 
6 
 
94,87% 
5,13% 
 
Hiperkolestrolemia 
- Yes 
- No 
4 
113 
3,4% 
96,6% 
 
Kidney Infection 
- Yes 
- No 
5 
112 
4,3% 
95,7% 
Comedication 
Folid Acid 
- Yes 
- No 
 
102 
15 
 
87,2% 
12,8% 
 
Calcium Carbonat 
- Yes 
- No 
 
82 
35 
 
70,1% 
29,9% 
 
Antihypertensive drugs 
- Yes 
- No 
96 
21 
82,1% 
17,9% 
 
Antidiabetic drugs 
- Yes 
- No 
27 
90 
23,1% 
76,9% 
 
Anti platelet 
- Yes 
- No 
11 
106 
9,4% 
90,6% 
 
Lipid lowering drug 
- Yes 
- No 
6 
111 
5,1% 
94,9% 
 
Hematopoetic agent 
- Yes 
- No 
 
97 
20 
 
82,9% 
17,1% 
Comorbidities 
<2 Comorbidities 
≥2 Comorbidities 
11 
106 
9,4% 
90,6% 
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Table 2. Quality of life scores (SF-8 score) in the pre and post test 
Variabel Pre test  Post Test p-value 
Median 
SF-8 Total Score  21,00 20,00 0,055 
SF-8 Physical Score  14,00 13,00 0,138 
SF-8 Mental Score  7,00 6,00 0,071 
*Non-Parametric - Wilcoxon 
 
The data used in this study is still in a scale 8 (minimum) - 
42 (maximum) based on the scoring of the questionnaire. At 
the first visit before receiving the vitamin (pre-test), the 
median total quality of life score (physical + mental) was 
21,00. Then when filling out the questionnaire after the 
respondents were given vitamins, there was a decrease in 
the average SF-8 total score to 20,00. The smaller the SF-8 
score obtained can indicate that the quality of life is getting 
better, and the greater the score obtained, the worse the 
quality of life. 
The questionnaire used in this study was an SF-8 
questionnaire containing 8 questions. Questions number 1-5 
are questions with a physical domain and questions number 
6-8 are questions with a mental domain. In assessing the 
physical quality of life score (SF-8 physical) at the first visit 
and subsequent visit, there was a decrease in the median 
physical SF-8 score from 14,00 to 13,00 . In assessing the 
mental quality of life score at the first visit and subsequent 
visit, there was also a decrease in the median mental SF-8 
score from 7,00 to 6,00. Can be seen in the table of p-value 
values from pre and post test (p-value> 0.05), it can be 
concluded that there were no significant changes in the 
results of pre and post administration of vitamins B1, B6, 
and B12. The analysis used to determine changes in quality 
of life in this study was paired t-test, but in the total score, 
physical score and mental score did not meet the normality 
requirements of the data, so that non-parametric Wilcoxon 
analysis was carried out.
 
Table 3. Analysis of SF-8 questions aspects between before and after administration of parenteral vitamins B1, B6, and B12 
 
Variabel 
Pre-Test Post-Test p-value 
                       Median  
General Health Perception 3,00  3,00 0,455 
Physical Functioning 3,00 3,00 0,071 
Physical Role Functioning 2,00 2,00 0,425 
Bodily Pain 3,00 3,00 0,267 
 Vitalitity 2,00 2,00 0,736 
 Social Functioning 3,00 3,00 0,474 
Mental Health 2,00 2,00 0,041 
Mental Role Functioning 2,00 2,00 0,145 
*Non-Parametric – Wilcoxon 
 
Based on the results of the analysis of aspects of the 
questions from the SF-8 questionnaire consisting of 8 
questions, presented in Table. 3. In the SF-8 question 
analysis Bonferroni correction was performed, so that the 
p-value limit value was 0.006 (p-value 0.05 divided by 8 = 
0.006). It can be concluded that there was no significant 
difference between the results of pre and post 
administration of vitamins B1, B6, and B12 (p-value> 0.006). 
The data used in the analysis of the SF-8 aspect is still on a 
scale of 8-42 (minimum score = 8 and maximum score = 42), 
so that the higher median of the score, it means the worse 
quality of life.
 
Table 4. Quality of life based on age group, gender and comorbidites 
 
Variabel 
SF 8 total  
Pre-Test  
SF 8 total  
Post-Test  
 
p-value 
             Mean ± SD  
Age a 
  <56 years 
  ≥ 56 years 
 
20,20 ± 5,10 
20,15 ± 4,46 
 
19,26 ± 5,38 
19,27 ± 4,23 
 
0,187 
0,200 
 Median 
Male  b 21,00 19,00             0,016*   
Female b 20,50 21,00 0,959 
Comorbidities < 2 b 19,00 19,00 0,645 
Comorbidities  ≥ 2 b 21,00 20,00 0,063 
a. Paired t- test   b. Non-Parametric - Wilcoxon 
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The existence of a relationship that was statistically 
significant in sex in the male group (p-value = 0.016) as a 
confounding variable on total quality of life (p-value <0.05). 
While other confounding variables such as age, female sex, 
comorbidities <2 and comorbidities ≥ 2 there was no 
significant relationship with the quality of life of the total 
subjects (total SF-8) (p-value> 0.05). In the analysis 
sub-group table for the age group analysis was carried out 
with paired t-test, whereas in the sex and comorbid groups 
an analysis was performed with the Wilcoxon 
non-parametric test because it did not meet the data 
normality requirements. 
DISCUSSION 
In this study, the characteristics of respondents undergoing 
hemodialysis from the two hospitals namely Bethesda 
Hospital and Yogyakarta Panti Rapih Hospital were mostly 
male, as many as 73 people (62.4%) compared to female 
sexes, as many as 44 people (37, 6%) of the total 
respondents, 117 people. The results of the same study can 
be found in the previous study at Bethesda Hospital in 
Yogyakarta who received 47 people (62.7%) who were 
undergoing hemodialysis with male sex and 28 people 
(37.3%) female sex .[3] This is also the same in a other study 
of 320 respondents found 183 people (57.2%) were male 
and 137 people (42.8%) were female.[4] The prevalence of 
chronic kidney disease is more prevalent among male than 
female.[4] 
The mean age of the subjects in this study was 51.58 + 12.51 
years. This is similar to the study that the average age of 
patients undergoing hemodialysis was 52.5 ± 15.9 years.[5] 
The average value of hemoglobin in this study was 9,228 ± 
1,488, this is similar to the previous research which is 9.4 ± 
1.7.10.[6] The value of hemoglobin in this study was found to 
be below the normal value so that the results of the study it 
was found that 111 of 117 patients had anemia. Anemia 
occurs when there is a hypoxic response due to a reduction 
in the functional renal parenchyma so that erythropoietin 
deficiency is produced by peritubular cells. In patients with 
chronic kidney disease, the body is not able to stimulate 
peritubular fibroblasts in the kidneys to increase EPO 
(erythropoetin) production so that anemia develops. The 
other factors that cause anemia are iron deficiency, vitamin 
deficiency, decreased life span of erythrocytes that 
experience hemolysis due to bleeding, and hemodialysis 
plays a role in the process of anemia in patients with chronic 
kidney disease because most red blood cells will be damaged 
during the hemodialysis process.[7]  
Summary of the total SF-8 score, PCS (Physical Component 
Score), and MCS (Mental Component Score), in this study 
there was no significant change in the post given 
combination of B vitamins as much as eight times per 
hemodialysis for 4 weeks (p-value >0.005). Previous 
research examined the effectiveness of combination vitamin 
B (B1, B6, and B12) on improving the quality of life in 
hepatitis patients.[8] Results of the study in the fourth week 
have not found significant changes in quality of life. After 24 
weeks there was a significant improvement in quality of life, 
the patient's PCS score was> 30 (average) and the patient's 
MCS score was> 50 (normal) and in the 48th week all PCS 
scores and MCS patients there were more patients who 
scored 50 or more as measured by the SF-36 questionnaire. 
This shows a significant increase in physical and mental 
quality of life in patients with chronic disease after giving 
vitamins for 24 weeks - 48 weeks.[8] Based on that research, 
it can be concluded that it takes longer time to administer 
vitamins at This study looks at the effectiveness of 
combination B vitamins for a significant improvement in 
quality of life in patients with chronic kidney disease 
undergoing hemodialysis. 
From the analysis that has been done can be seen in Table. 3 
regarding the analysis of aspects of SF-8 questions on 117 
respondents. After the Wilcoxon non parametric test was 
carried out due to abnormal data distribution There were 
changes in the eight aspects of the SF-8 question in the form 
of increasing scores, but the results were not statistically 
significant based on Bonferroni's correction (p> 0.006). This 
is similar to other research regarding the effectiveness of 
giving vitamin B12 to hemodialysis patients. Obtained a 
significant improvement in the quality of life of post 
treatment (vitamin B12) only on the aspect of social function 
(p = 0.047) after the combination of vitamin B for 3 months. 
This can be caused by a lack of long research time to observe 
the effectiveness of vitamin B in improving quality of life.[9] 
In this study, the most widely used comedication by patients 
was folic acid, which was obtained in 102 (87.2%) 
hemodialysis patients. Previous research has shown that 
folate deficiency is associated with depression because 
folate plays an important role in the process of methylation 
and synthesis of neurotransmitters in the central nervous 
system.[10] Increased homocysteine levels 
(hyperhomocysteinemia), is a sign of folate deficiency and 
vitamin B12 deficiency, which can eventually causing 
oxidative stress, resulting in cerebral brain damage, 
neurological damage and neurotransmitter deficiency.[11] In 
this study, most research subjects had received folic acid in 
order to avoid folate deficiency. Folic deficiency is associated 
with the occurrence of depression and cognitive decline in 
patients, while low vitamin B12 concentrations are mainly 
associated with cognitive impairment. The combination of 
folic acid and vitamin B combination plays an important role 
to increase the summary score of the mental components of 
hemodialysis patients to prevent folate and vitamin B12 
deficiency.[12]  
In this study, the relationship between the factors that 
influence total quality of life (SF-8 Total) was measured in 
patients undergoing hemodialysis. Subgroup analysis could 
show a significant change in the male group with a value of p 
<0.05 (p = 0.016) which showed that there was a significant 
increase in quality of life after administration of vitamins B1, 
B6, and B12 in the male group research subjects . In the 
female group no significant changes were found (p = 0.959) 
and the median quality of life pre and post vitamin 
administration was increase and this showed that female 
had a worse quality of life than male. The results of the study 
in the female’s group can be influenced by the small number 
of female patients and the uneven distribution of female's 
data. 
In this study there were age groups <56 years and ≥56 years, 
but no significant changes were found in the 2 age groups. In 
comorbidities, there were 2 groups, namely groups of 
patients with comorbidities <2 and patients with 
comorbidities ≥2 and no significant results (p> 0.05). 
Comorbidity is another condition besides chronic kidney 
disease which consequently can affect other organs. This 
condition can also be a factor that causes chronic kidney 
disease, such conditions as hypertension and diabetes.[12] 
Most patients in this study suffered from hypertension, 
followed by diabetes, cardiovascular disease. As many as 
94.87% of patients have anemia and 90.6% have more than 
two comorbidities. The presence of other chronic diseases as 
comorbidities greatly influences the quality of life of patients 
with chronic kidney disease undergoing hemodialysis, 
therefore it is very important to treat treatment for 
comorbidity because it can help improve the quality of life of 
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patients with chronic kidney disease who experience 
hemodialysis.[12]  
The limitation of this study was that this study was carried 
out for 4 weeks, therefore changes and improvement in 
quality of life after administration of vitamins B1, B6, and 
B12 had not occurred significantly. This study also did not 
have a treatment control group (not given vitamins), so it 
could not measure and compare the quality of life in patients 
with chronic kidney disease who received vitamin B1, B6, 
and B12 therapy with the control group (not given 
vitamins). 
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